Liquid CMO seeks osteoarthritis and fibromyalgia patients for pilot study in Phoenix
February 12, 2016
"VT-346 surprised us in pre-clinical studies when it demonstrated up to one hundred fold better inhibition of human TNF when compared to currently marketed therapies," said Dr. Mike Gresser, former Head of Inflammation and Neuroscience research at Amgen and consultant to Viron. "From this potent impact in primary human tissue, it seems VT-346 was doing something fundamentally different from existing anti-TNF products. More recent characterization of the molecule has provided some key insights into this distinct mechanism of action and allowed us to file some new patents. We are currently discussing this mechanism of action under strict confidentiality with interested partners."
"The results from our VT-346 program results continue to validate the ability of our PROSPECT(TM) platform for generating innovative and potent therapeutics," said James Rae, CEO of Viron. "In addition to the potential for VT-346 as an anti-TNF therapy, we have also filed new patents on the use of VT-346 to aid in the discovery of antibodies that mimic its unique mechanistic profile, making this program both a drug candidate and a potential platform for the identification of new and unique anti-TNF therapies."
Viron researchers selected this animal model of arthritis due to its accurate prediction of clinical benefits for the currently marketed anti-TNF therapeutics. These animal model results build on early pre-clinical in vitro testing and characterization of this compound that was conducted using human tissues to demonstrate potent anti-inflammatory activities. Studies were conducted by BioMedCode, a recognized leader in the use of this transgenic model.SOURCE Viron Therapeutics Inc.